companydata.dkcompanydata.dk

Commit Biologics ApS: Financial statements 2023

CVR: 42642649

Source: annual report 2023, Danish Business Authority

01/01/202331/12/2023

Commit Biologics ApS (CVR 42642649) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -13,580,251 and a net result of DKK -17,295,813. Equity in the 2023 report amounted to DKK 22,578,793. The solvency ratio was 96.8%. The company had 10 employees in the financial year.

Gross Profit
DKK -13,580,251
Profit/Loss
DKK -17,295,813
Equity
DKK 22,578,793
Total Assets
DKK 23,325,997
Employees
10

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2023

Krishna Reddy Polu joins the board of Commit Biologics ApSAug 24, 2023

As of August 24, 2023, Krishna Reddy Polu has joined the board of directors of Commit Biologics ApS.

Krishna Reddy Polu joins Commit Biologics ApS as adm. dir.Aug 24, 2023

As of August 24, 2023, Krishna Reddy Polu is registered as adm. dir. of Commit Biologics ApS.

Nick Stub Laursen steps down as director of Commit Biologics ApSAug 24, 2023

As of August 24, 2023, Nick Stub Laursen has stepped down as director of Commit Biologics ApS.

Commit Biologics ApS publishes interim reportMay 4, 2023

Commit Biologics ApS has published its interim report for the period September 1, 2021 – December 31, 2022.

Anker Gunvald Lundemose joins the board of Commit Biologics ApSFeb 1, 2023

As of February 1, 2023, Anker Gunvald Lundemose has joined the board of directors of Commit Biologics ApS.

Commit Biologics ApS appoints new auditorJan 31, 2023

As of January 31, 2023, KOVSTED & SKOVGÅRD, REVISION & RÅDGIVNING, STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Commit Biologics ApS.

About Commit Biologics ApS

Commit Biologics ApS is a Danish company of the type Anpartsselskab based in Aarhus C, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Thomas Lars Andresen. The company's owners include Novo Holdings A/S, Commit Biologics Holding ApS and Bioqube Factory Fund I CommV. In 2025, the company reported a gross profit of DKK -23,365,247 and a net result of DKK -33,781,079 compared with DKK -39,360,775 the year before. Equity in the 2025 report amounted to DKK 37,898,027.

Source: annual report 2025, Danish Business Authority

Other financial years